drugset / Trial / NCT01018758

Study With Palonosetron Alone in Preventing Chemotherapy-induced Nausea and Vomiting in Untreated Patients With Aggressive Non Hodgkin's Lymphomas Who Underwent Moderately Emetogenic Chemotherapy

NCT01018758

Phase 2 Completed 86 enrolled Gruppo Italiano Studio Linfomi
NaSingle-groupOpen-labelPrevention

Summary

This is an open-label, multicenter phase II study in patients with aggressive Non Hodgkin Lymphoma scheduled to receive moderately emetogenic polychemotherapy (according to modified Hesketh classification for antiemetic therapy).

Timeline

Start
2006-07
Primary completion
Completion
2008-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Palonosetron Other / unclassified 250 ug Intravenous